Read More Pharma Industry News Why Cyclin E1 biomarker targeting may become central to next-generation ovarian cancer therapies Find out why Zentalis Pharmaceuticals’ Cyclin E1 strategy could reshape ovarian cancer treatment and investor sentiment into 2026. bySoujanya RaviApril 12, 2026